Skip to main content
NewslettersWatchlist

Illumina Inc(ILMN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low117.48
Day High120.99
Open:118.58
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
Stocks Rebound as Bond Yields Fall Ahead of Wednesday’s US CPI Report
Barchart
Stocks Retreat on Risk Aversion Ahead of Wednesday’s US CPI Report
Barchart
Stocks Mixed Before Wednesday’s US CPI Report
Motley Fool
Why Illumina Stock Zoomed Higher on Thursday
Barchart
Stock Indexes Rally to Record Highs on a Resilient US Economy
Barchart
Stock Indexes Post Record Highs on Rate Cut and Soft-Landing Optimism
Barchart
Stock Indexes Climb to Record Highs on Expectations for Fed Rate Cuts
Motley Fool
Why Illumina Stock Mashed the Market on Monday
Barchart
Stocks Fade Ahead of This Week’s Economic Reports
Barchart
Stocks Mixed as Investors Await Fresh Economic News
Barchart
Stocks Slightly Higher Ahead of This Week’s U.S. Economic Reports
Barchart
S&P 500 and Nasdaq 100 Set Record Highs on Economic Optimism
Barchart
Stocks Gain on Fed-Friendly Inflation Report
Motley Fool
Why Illumina Rallied 36.6% in December
The Globe and Mail
Market movers: Stocks seeing action on Monday - and why
The Associated Press
Biotech giant Illumina will unwind takeover of cancer-screening company Grail
Newswire.ca
Bahrain, First in the Middle East to Acquire Latest Machine used for Human Genome Sequencing
Baystreet
TSX Moves Tentative Ahead
PR Newswire
Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research
MarketBeat
3 Nasdaq-100 Stocks Trading Less Than 10x 2024 Earnings
PR Newswire
Illumina responds to European Commission's divestiture order
PR Newswire
Illumina Posted a Stewardship-Focused Presentation for Investors
Barchart
Stocks Recover Early Losses on Dovish Fed Remarks
Barchart
Stocks Higher Despite Middle East Turmoil
MarketBeat
3 Undervalued Healthcare Stocks to Watch as Sector Struggles
PR Newswire
Illumina to Announce Third Quarter 2023 Financial Results on Thursday, November 9, 2023
BayStreet.ca
Advancements in Pancreatic Cancer Treatment: Biotech Innovations and Rising Optimism
Motley Fool
Is the Worst Over for Illumina Stock?
Motley Fool
Cathie Wood's Buying These 3 Stocks Hand Over Fist
Barchart
Broad Market Sags on Global Economic Concerns and Higher Bond Yields
Barchart
Stocks Mixed as Weak China and European Economic News Sparks Risk-Off Sentiment
PR Newswire
Illumina's Board Appoints Jacob Thaysen, Ph.D. as its New Chief Executive Officer

Profile

Illumina Inc. is a life sciences company, which provides tools and integrated systems for analysis of genetic variation and function. Using its proprietary technologies, the company provides innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, and gene expression profiling of DNA and RNA. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Illumina generates revenue from two segments - Product and Service. Product are primarily attributed to the partnerships and collaborations to develop distributable clinical in-vitro diagnostics for Illumina sequencers. Service include genotyping and sequencing services as well as instrument maintenance contracts.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.